Bellus Health Inc. - a GSK company
19
0
2
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
5.3%
1 terminated/withdrawn out of 19 trials
92.9%
+6.4% vs industry average
26%
5 trials in Phase 3/4
31%
4 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Role: lead
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
Role: lead
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Role: lead
Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation
Role: lead
Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
Role: lead
A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants
Role: lead
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Role: lead
Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
Role: lead
A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
Role: lead
Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937
Role: lead
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Role: lead
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
Role: lead
BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect
Role: lead
A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes
Role: lead
European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients
Role: lead
Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease
Role: lead
Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease
Role: lead
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Role: lead
Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
Role: lead
All 19 trials loaded